Pharmaceuticals

The forefront of innovation

Share

The pharmaceutical industry is facing a period rich with opportunity and uncertainty as businesses are confronted by the need to generate growth in a mature, competitive market while faced with increasing pricing pressures and contracting margins.

Blockbuster patent expiries and the entry of biosimilar products has seen innovative pharmaceutical companies change direction, resulting in a blurring of traditional lines in the market. Coupled with unprecedented collaboration between global players, this is driving innovative approaches to commercialising IP and transformative asset-driven transactions.

Combining deep scientific and technical knowledge, we apply our commercial nous and experience to anticipate and deliver innovative, value-enhancing solutions.

We partner with our clients at every level of their businesses to help them achieve their goals: from strategic advice on "bet-the-company" transactions and disputes to merger control, regulatory investigations, commercial contracts and licensing.

Our intellectual property lawyers, the majority of whom have scientific or engineering backgrounds, understand that innovation is at the heart of the pharmaceutical industry. We help the world's leading pharmaceutical companies to use intellectual property to achieve commercial outcomes and competitive advantage, and have acted on some of the most complex transactions and disputes in the market.

Our integrated pharmaceuticals team spans our network of offices, and together with our preferred, trusted local law firms, work as one to provide commercial solutions—wherever you operate. 



Accolades

'Excellent patent litigation offering for biotech and pharmaceutical companies, best known for defending against generic challenges. Very strong on the interaction of IP law with competition and EU law. Also advises on IP licensing and freedom-to-operate exercises. Demonstrates expertise in UK and EU pharmaceutical regulations.' 
Life Sciences: Patent Litigation, Chambers UK, 2020

"They are exceptional and I wouldn't hesitate to recommend them. They are very personable, they got to understand our business quickly and the service was first class." (Client quote)
Life Sciences: Patent Litigation, Chambers UK, 2020

'The team is highly recommended for their IP and regulatory skills, combining advice and litigation capabilities.'
Life Sciences & Healthcare, Legal 500 Italy

"We enjoy their worldwide presence and use them in Australia and other jurisdictions; they are able to co-ordinate big, worldwide legal battles and it's good to have a network of lawyers working together for a common goal." (Client quote)
Life Sciences, Chambers Asia-Pacific: Australia 2020

‘A top-tier team, very impressive.’ (Client quote)
Pharmaceuticals & Biotechnology, Legal 500 UK 2020

"our go-to firm in Australia – there's no need to look elsewhere." Another reports: "They are the only firm that has the capacity to advise across the board for all areas of our business, which is why we keep using them. They do the stuff that requires hard thinking. ." (Client quote)
Life Sciences, Chambers Asia-Pacific: Australia 2020

‘The lawyers combine the high quality and sophisticated knowledge of a boutique law firm with the approach, mind-set and language skills of an international firm. So what we get is a combination of high-quality legal advice given to us in a very concise, practical and helpful way.' (Client quote)
Life Sciences & Healthcare, Legal 500 Italy

Rankings

Tier 1, Pharmaceuticals & Biotechnology
Legal 500 UK 2020

Band 1, Life Sciences
Chambers Australia 2020

Tier 3, Life Sciences & Healthcare
Legal 500 Italy 2020

Team Awards

Firm of the Year: Patent Strategy & Management 
LMG European Life Sciences Awards 2020

Firm to Watch: Litigation & Enforcement
LMG European Life Sciences Awards 2020

Life Sciences Firm of the Year – Italy 
LMG European Life Sciences Awards 2020

Learn more about how we help our clients in

Pharmaceuticals and Healthcare

View Sector

Recent Experience

Abcam Plc

Advising Abcam on its acquisition of Expedeon AG's proteomics and immunology business for €120m

Lupin Limited

Advising Lupin, on the sale of its entire stake in its Japanese subsidiary, Kyowa Pharmaceutical Industry Co., Ltd. (Kyowa), to Unison Capital for JPY 57.4 billion (c.US$525 million)

Strides Pharma Science Limited

Advising Strides Pharma Science Limited, an Indian listed pharmaceuticals company, on the AU$394 million sale of its entire Australian business, including Arrow Pharmaceuticals, to Arrotex

Genus Plc

Advising Genus, a UK listed animal genetics company, on its strategic partnership with Beijing Capital Agribusiness Co. Ltd (BCA) to research, develop, register and market pigs resistant to Porcine Reproductive and Respiratory Syndrome virus (PRRSv) in China

Impilo

Advising Impilo, a Nordic-based investment company that focuses exclusively on investments in healthcare companies active in the areas of pharmaceuticals, medical technology, healthcare services and other health-related areas, on its leveraged buy-outs of The Fertility Partnership and Viva Neo - leading European providers of fertility services, ultrasound pregnancy scans and hormone treatments

Hoffmann La-Roche AG and Roche Products Limited (Roche)

Advising F. Hoffmann La-Roche AG and Roche Products Limited (Roche) in a significant High Court victory against Pfizer, in an action concerning Avastin®, Roche's blockbuster treatment for various forms of cancer. The action centred on whether a UK court should grant a form of negative declaratory relief known as an "Arrow declaration" in circumstances where our client had no relevant patent rights in the UK, and the claimant (Pfizer) intended to use the declarations and judgment solely for the purposes of influencing foreign courts.

Diverse Knowledge, in-depth experience